SML3594

Masitinib

≥98% (HPLC)

• Synonyme(s) : 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, AB1010
• Formule empirique (notation de Hill) : C₂₈H₃₀N₆OS
• Numéro CAS: 790299-79-5
• Poids moléculaire : 498.64
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD09954132
• Assay: ≥98% (HPLC)
• Form: powder

Propriétés

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: CC1=CC=C(NC(C2=CC=C(CN3CCN(C)CC3)C=C2)=O)C=C1NC4=NC(C5=CN=CC=C5)=CS4
• InChI: 1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
• InChI key: WJEOLQLKVOPQFV-UHFFFAOYSA-N

Description

Biochem/physiol Actions

Masitinib is a protein tyrosine kinase inhibitor that selectively targets stem cell factor receptor c-kit in particular and also PDGFRalpha/beta and Lyn. It is more potent and selective for c-kit than imatinib (Gleevec). Masitinib has antineoplastic and anti-inflammatory activity. It inhibits the survival, migration and activity of mast cells, key components of the inflammation response. It is used to treat mast cell tumors in dogs and is in clinical trials for human use in rheumatoid arthritis, asthma, and as an adjuct therapy for Alzheimer′s disease.

c-kit/PDGF receptor tyrosine kinase inhibitor

Informations sur la sécurité

• Pictogrammes: GHS08,GHS07
• Mot-clé: Warning
• Codes de danger: H302,H361d,H373
• Mentions de précaution: P202 - P260 - P264 - P280 - P301 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Repr. 2 - STOT RE 2
• Classe de stockage: 11 - Combustible Solids
• Que se passe-t-il ?: WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable